Key result
Carboxyethylpyrrole plasma biomarkers, when evaluated alongside genomic markers, provide the potential to assess age-related macular degeneration susceptibility with approximately 80% accuracy.
Why the study?
Does Carboxyethylpyrrole (CEP) plasma biomarker assessment improve the accuracy of assessing AMD susceptibility in high-risk patients?
Does Carboxyethylpyrrole (CEP) plasma biomarker assessment improve the accuracy of assessing AMD susceptibility in high-risk patients?
Carboxyethylpyrrole (CEP) is a promising plasma biomarker that, alongside genomic markers, can assess age-related macular degeneration susceptibility with approximately 80% accuracy.
Answers are grounded in this paper and cite their sources.
May support combined biomarker-genomic AMD risk assessment; leaves open clinical utility pending prospective validation.
Age-related macular degeneration causes irreversible central blindness in people over the age of 50 and is increasing in prevalence among elderly populations.There are currently limited treatment options available for the exudative form of the disease and no formal treatments for the geographic atrophy form aside from lifestyle change and incorporation of antioxidant supplements in the diet.As such, it is important to be able to assess high-risk AMD patients as early as possible in order to prescribe preventative measures.Carboxyethylpyrrole (CEP) is a promising plasma biomarker suited to this purpose.Both CEP immunoreactivity levels as well as anti-CEP autoantibody titers are significantly elevated in AMD patients and thus provide the potential to assess AMD susceptibility with approximately 80% accuracy when evaluated alongside genomic AMD markers.Moreover, strong evidence implicates CEP as functionally related to AMD pathogenesis, a role which must be explored further.This avenue of research will foster improved understanding of the disease itself and perhaps reveal better therapeutic targets and options.Further research into the role of CEP in AMD pathogenesis and the application of CEP as an AMD biomarker is merited.
No takes yet. Share an insight, caveat, or question.
Ardeljan et al. (2011) conducted a review in Age-related macular degeneration. Carboxyethylpyrrole (CEP) plasma biomarkers was evaluated on AMD susceptibility assessment accuracy. Carboxyethylpyrrole plasma biomarkers, when evaluated alongside genomic markers, provide the potential to assess age-related macular degeneration susceptibility with approximately 80% accuracy.
Synapse has enriched 10 related papers. Consider them for comparative context: